Patents Assigned to JANSSEN SCIENCES IRELAND UC
  • Combination and uses and treatments thereof
    Patent number: 12011506
    Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: June 18, 2024
    Assignees: ViiV Healthcare Company, Janssen Sciences Ireland UC
    Inventors: Kenneth Churchill Campbell, Urbain Alfons C. Delaet, James M. Goodrich, Juliette Segolène Guaquière, Thomas Laughery, Dominique J. Limet, John C. Pottage, Ludovic Sylvain Marc Renou, Trevor R. Scott, Christian Seiler, Mary Woodward
  • Darunavir combination formulations
    Patent number: 11654150
    Abstract: This invention relate to solid oral dosage forms of tire HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulation thereof.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Janssen Sciences Ireland UC
    Inventors: Urbain Alfons C. Delaet, Philip Erna H. Heyns, Eugeen Maria Jozef Jans, Roel Jos M. Mertens, Geert Van Der Avoort
  • Antibacterial Compounds
    Publication number: 20230014173
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 19, 2023
    Applicant: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Pyrimidine derivatives for the treatment of viral infections
    Patent number: 11541050
    Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: January 3, 2023
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: David Mc Gowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
  • Antibacterial compounds
    Patent number: 11180472
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 23, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Heterocyclic compounds as antibacterials
    Patent number: 11179396
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 11078193
    Abstract: Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: August 3, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Geerwin Yvonne Paul Haché, Stefaan Julien Last, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10995064
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 4, 2021
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10941113
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: March 9, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Pierre Jean-Marie Bernard Raboisson
  • Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10875876
    Abstract: Inhibitors of HBV replication of Formula (I-A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: December 29, 2020
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Sandrine Marie Helene Vendeville, Stefaan Julien Last, Samuël Dominique Demin, Sandrine Céline Grosse, Geerwin Yvonne Paul Haché, Lili Hu, Serge Maria Aloysius Pieters, Geert Rombouts, Koen Vandyck, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
    Patent number: 10857102
    Abstract: The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: December 8, 2020
    Assignees: Gilead Sciences, Inc., Janssen Sciences Ireland UC
    Inventors: Reza Oliyai, Lauren Wiser, Mark Menning
  • Compositions and methods of treating HIV
    Patent number: 10786518
    Abstract: The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: September 29, 2020
    Assignees: Janssen Sciences Ireland UC, Gilead Sciences, Inc.
    Inventors: Katia Boven, Goedele De Smedt, Regina Driesen, Dominiek Henrist, Greet Kauwenberghs, Sandeep Mathur, Scott McCallister, Roel Mertens, Richard Nettles, Magda Opsomer, William Pyrz, Vahid Zia
  • Pyrimidine derivatives for the treatment of viral infections
    Patent number: 10780089
    Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: September 22, 2020
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
  • ANTIBACTERIAL COMPOUNDS
    Publication number: 20200239434
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Applicant: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
    Patent number: 10676429
    Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: June 9, 2020
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Geert Rombouts, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Heterocyclic indoles for use in influenza virus infection
    Patent number: 10626108
    Abstract: The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: April 21, 2020
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Tim Hugo Maria Jonckers, David Craig McGowan, Jérôme Émile Georges Guilllemont, Ludwig Paul Cooymans, Werner Constant Johan Embrechts, Christophe Francis Robert Nestor Buyck, Wendy Mia Albert Balemans, Pierre Jean-Marie Bernard Raboisson
  • Aryl substituted pyrimidines for use in influenza virus infection
    Patent number: 10611755
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: April 7, 2020
    Assignee: Janssen Sciences Ireland UC
    Inventors: Tim Hugo Maria Jonckers, David Craig McGowan, Jérôme Émile Georges Guillemont, Werner Constant J Embrechts, Guillaume Jean Maurice Mercey, Christophe Francis Robert Nestor Buyck, Wendy Mia Albert Balemans, Pierre Jean-Marie Bernard Raboisson
  • Indoles for use in influenza virus infection
    Patent number: 10597390
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 24, 2020
    Assignee: Janssen Sciences Ireland UC
    Inventors: Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Jérôme Émile Georges Guillemont, David Craig McGowan, Werner Constant Johan Embrechts, Ludwig Paul Cooymans, Antoine Benjamin Michaut
  • Functionalized pentanoic acids for use influenza viral infections
    Patent number: 10526338
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: January 7, 2020
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Wendy Mia Albert Balemans, David Craig McGowan, Magali Madeleine Simone Motte, David Francis Alain Lançois, Emilie Marie Lambert
  • Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
    Patent number: 10501445
    Abstract: Quinoxalinones and dihydroquinoxalinones having inhibitory activity on RSV replication and having the formula I including addition salts, and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: Abdellah Tahri, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Samuel Dominique Demin